Feature

Resveratrol and Diabetic Retinopathy

Could a multi-target molecule be used for earlier intervention of DR?

  • By

  • February 23, 2026

  • 3 min

Share

  • 1

    Diabetic retinopathy treatments are mainly reactive.

  • 2

    Resveratrol is identified as a potential multi-target modulator for early DR.

  • 3

    It influences mitochondrial health, inflammatory signaling, and neuroglial behavior.

  • 4

    Resveratrol has shown protective effects on retinal structure in preclinical studies.

  • 5

    Its anti-inflammatory properties involve suppression of multiple mediators.

  • 6

    Current evidence for resveratrol is preclinical and not yet suitable for clinical use.

Original Source(s)

Resveratrol and Diabetic Retinopathy

Could a multi-target molecule be used for earlier intervention of DR?

  • February 23, 2026

  • 3 min

Related Content

Can Diabetic Eye Testing Be Simplified?

Three-test models matched nine-test battery in classifying disease stages

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.